Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core

Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core

The use of p53-MDM2 inhibitors is a prospective strategy in anti-cancer therapy for tumors expressing wild type p53 protein. In this study, we have applied a simple approach of two-step synthesis of imidazoline-based alkoxyaryl compounds, which are able to efficiently inhibit p53-MDM2 protein–protei...

Full description

Bibliographic Details
Main Authors: Daniil R. Bazanov, Nikolay V. Pervushin, Egor V. Savin, Michael D. Tsymliakov, Anita I. Maksutova, Victoria Yu. Savitskaya, Sergey E. Sosonyuk, Yulia A. Gracheva, Michael Yu. Seliverstov, Natalia A. Lozinskaya, Gelina S. Kopeina
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Pharmaceuticals
Subjects:
nutlins
cis-imidazolines
p53-MDM2 inhibitors
anti-cancer
Online Access:https://www.mdpi.com/1424-8247/15/4/444

Internet

https://www.mdpi.com/1424-8247/15/4/444

Similar Items